Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Reiss

Showing results (111-120 of 301) with videos related to

Pageof 31
Sort By:
The Journal of Biological Chemistry|October 10, 1980
Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purificationP Y Wong, W H Lee, P H Chao, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 26, 2001
Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and olderB Williams, G Noonan, T F Reiss, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|May 7, 2011
The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthmaGeorge Philip, César Villarán, Shailen R Shah, et al.
The European Respiratory Journal|July 10, 1998
Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study GroupM J Noonan, P Chervinsky, M Brandon, et al.
The European Respiratory Journal|July 28, 2006
An oral selective M3 cholinergic receptor antagonist in COPDS Lu, D D Parekh, O Kuznetsova, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Design of the Fracture Intervention TrialD M Black, T F Reiss, M C Nevitt, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthmaI De Lepeleire, T F Reiss, F Rochette, et al.
Journal of Clinical Pharmacology|September 22, 2020
Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma ExacerbationsDonald H Arnold, Sara L Van Driest, Theodore F Reiss, et al.
The Journal of Allergy and Clinical Immunology|July 29, 1998
A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study GroupL C Altman, Z Munk, J Seltzer, et al.
Current Medical Research and Opinion|June 23, 2005
Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthmaJanet van Adelsberg, James Moy, Lynn X Wei, et al.
Pageof 31

Showing results (111-120 of 301) with videos related to

Sort By:
Pageof 31
The Journal of Biological Chemistry|October 10, 1980
Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purificationP Y Wong, W H Lee, P H Chao, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 26, 2001
Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and olderB Williams, G Noonan, T F Reiss, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|May 7, 2011
The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthmaGeorge Philip, César Villarán, Shailen R Shah, et al.
The European Respiratory Journal|July 10, 1998
Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study GroupM J Noonan, P Chervinsky, M Brandon, et al.
The European Respiratory Journal|July 28, 2006
An oral selective M3 cholinergic receptor antagonist in COPDS Lu, D D Parekh, O Kuznetsova, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1993
Design of the Fracture Intervention TrialD M Black, T F Reiss, M C Nevitt, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthmaI De Lepeleire, T F Reiss, F Rochette, et al.
Journal of Clinical Pharmacology|September 22, 2020
Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma ExacerbationsDonald H Arnold, Sara L Van Driest, Theodore F Reiss, et al.
The Journal of Allergy and Clinical Immunology|July 29, 1998
A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study GroupL C Altman, Z Munk, J Seltzer, et al.
Current Medical Research and Opinion|June 23, 2005
Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthmaJanet van Adelsberg, James Moy, Lynn X Wei, et al.
Pageof 31